Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded haploidentical NK cell infusion before autologous stem cell transplantation in high-risk neuroblastoma
IRCT20140818018842N32Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Dec 2022
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of expanded haploidentical NK cells in neuroblastoma, sponsored by Tehran University of Medical Sciences. Primary endpoints: 2-year survival rate, 2-year relapse rate and 1 more. Started Dec 2022; status: completed.
02
Drugs
expanded haploidentical NK cells
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on IRCT20140818018842N32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140818018842N32.